Revolution Medicines (RVMD) Preferred Stock Liabilities (2018 - 2019)
Revolution Medicines (RVMD) recorded quarterly Preferred Stock Liabilities of $305.1 million in Q4 2019, little changed quarter-over-quarter from $305.1 million in Q3 2019, and up 48.77% on a YoY basis from $205.1 million in Q4 2018.
Revolution Medicines (RVMD) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Revolution Medicines' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $305.1 million for Q4 2019.
- In Q4 2019, Preferred Stock Liabilities rose 48.77% year-over-year to $305.1 million; the TTM figure through Dec 2019 stood at $305.1 million (up 48.77% YoY), while the FY2019 annual figure was $305.1 million, up 48.77% from the prior year.
- Preferred Stock Liabilities was $305.1 million for Q4 2019 at Revolution Medicines, roughly flat from $305.1 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $305.1 million in Q3 2019 to a low of $205.1 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Revolution Medicines | 32.33 Bn | 32.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 305.11 Mn |
| Sep 30, 2019 | 305.11 Mn |
| Jun 30, 2019 | 295.02 Mn |
| Mar 31, 2019 | 205.08 Mn |
| Dec 31, 2018 | 205.08 Mn |